

1  
2  
3  
4  
5  
6  
7  
8 TEVA PHARMACEUTICALS USA, INC.,  
9 Plaintiff,  
10 v.  
11 CORCEPT THERAPEUTICS, INC., et al.,  
12 Defendants.

Case No. [24-cv-03567-NW](#) (VKD)

**ORDER RE MAY 2, 2025 DISCOVERY  
DISPUTE RE CORCEPT DOCUMENT  
REQUESTS**

Re: Dkt. No. 98

13  
14 Plaintiff Teva Pharmaceuticals USA, Inc. (“Teva”) and defendant Corcept Therapeutics,  
15 Inc. (“Corcept”) ask the Court to resolve their dispute regarding Corcept’s requests for four  
16 categories of documents from Teva. Dkt. No. 98. The Court held a hearing on this matter on May  
17 13, 2025. Dkt. Nos. 100, 103 (hearing transcript).

18 As framed by the parties, this dispute concerns four categories of documents Corcept  
19 requests from Teva:

20 1. *Orange Book*: Documents reflecting Teva’s practices in listing patents in the  
21 Orange Book.

22 2. *Sham litigation*: Documents reflecting Teva’s practices in initiating and  
23 maintaining patent infringement actions.

24 3. *Exclusive dealing*: Documents reflecting Teva’s use of exclusive dealing  
25 agreements.

26 4. *Physician payments*: Documents reflecting Teva’s payments to physicians in  
27 connection with its own drugs.

28 Dkt. No. 98 at 1.

For the reasons explained on the record during the hearing, the Court is not persuaded that


1 Teva's own practices regarding Orange Book listings or patent enforcement actions have any  
2 bearing on whether Corcept's own Orange Book listings and patent enforcement action were  
3 objectively baseless or reflect subjective bad faith. Conversely, Teva's own practices regarding  
4 exclusive dealing agreements and payments to physicians may yield information relevant to  
5 whether Corcept's conduct was reasonable and consistent with industry norms, which Corcept  
6 may then use to rebut Teva's allegations that Corcept's conduct is unusual and reflects anti-  
7 competitive behavior. Thus, the Court concludes that Corcept may not obtain discovery from  
8 Teva regarding the first and second categories, but may obtain discovery regarding the third and  
9 fourth categories.

10 Teva's objections regarding the burdensomeness of Corcept's requests are well-taken,  
11 given the number of drugs it offers. However, during the hearing Corcept suggested that the  
12 documents it seeks regarding Teva's exclusive dealing agreements and physician payments may  
13 be easily identified by means of database queries, and Teva conceded that it could undertake such  
14 queries. Dkt. No. 103 at 14:9-25; *see also id.* at 16:17-25. Corcept further suggested that a  
15 representative sample may be sufficient. *Id.* at 13:18-20.

16 Accordingly, the Court orders the parties to confer regarding parameters defining a  
17 representative sample of responsive documents within the third and fourth categories described  
18 above. **By May 23, 2025**, the parties shall file a joint status report describing their agreed or  
19 respective proposals for Teva's production of these documents.

20 **IT IS SO ORDERED.**

21 Dated: May 16, 2025

22  
23   
24 Virginia K. DeMarchi  
United States Magistrate Judge

25  
26  
27  
28